HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Cancer Cell

• Publication date

  2004-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.CCR.2004.09.031PMID 15542435
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Her-2/neu Expression in Prostate Cancer

  2004cited by this paper
• Molecular determinants of resistance to antiandrogen therapy

  2004cited by this paper
• Androgen receptor outwits prostate cancer drugs

  2004cited by this paper
• The Androgen Axis in Recurrent Prostate Cancer

  2004cited by this paper
• Phosphorylation of androgen receptor isoforms.

  2004cited by this paper
• Epidermal Growth Factor Increases Coactivation of the Androgen Receptor in Recurrent Prostate Cancer*

  2004cited by this paper
• Androgen-induced recruitment of RNA polymerase II to a nuclear receptor–p160 coactivator complex

  2003cited by this paper
• Small-interfering RNAs in the radar of the interferon system

  2003cited by this paper
• Growth factor receptor tyrosine kinase inhibitors; clinical development and potential for prostate cancer therapy.

  2003cited by this paper
• Human epidermal receptor-2 expression in prostate cancer.

  2003cited by this paper
• Diverse roles for ubiquitin-dependent proteolysis in transcriptional activation

  2003cited by this paper
• Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer

  2003cited by this paper
• Suppression Versus Induction of Androgen Receptor Functions by the Phosphatidylinositol 3-Kinase/Akt Pathway in Prostate Cancer LNCaP Cells with Different Passage Numbers*

  2003cited by this paper
• The embedded tumour: host physiology is important for the evaluation of tumour growth

  2003cited by this paper
• The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

  2003cited by this paper
• The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity.

  2003cited by this paper
• Formation of the androgen receptor transcription complex.

  2002cited by this paper
• Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.

  2002cited by this paper
• Phosphorylation‐dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase

  2002cited by this paper
• Androgen Receptor Phosphorylation

  2002cited by this paper
• Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts.

  2002cited by this paper
• Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer.

  2002cited by this paper
• Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor

  2001cited by this paper
• Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.

  2001cited by this paper
• Growth Factors Signal to Steroid Receptors through Mitogen-activated Protein Kinase Regulation of p160 Coactivator Activity*

  2001cited by this paper
• HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer.

  2001cited by this paper
• The epidermal growth factor receptor as a target for cancer therapy.

  2001cited by this paper
• Tyrosine kinase inhibitors: From rational design to clinical trials

  2001cited by this paper
• Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease.

  2001cited by this paper
• The ErbB signaling network: receptor heterodimerization in development and cancer

  2000cited by this paper
• The prostate: development and physiology.

  2000cited by this paper
• Inhibiting proteasomes in human HepG2 and LNCaP cells increases endogenous androgen receptor levels.

  2000cited by this paper
• Phosphorylation of Steroid Receptor Coactivator-1

  2000cited by this paper
• Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome.

  2000cited by this paper
• The SMRT Corepressor Is Regulated by a MEK-1 Kinase Pathway: Inhibition of Corepressor Function Is Associated with SMRT Phosphorylation and Nuclear Export

  2000cited by this paper
• Her-2-neu expression and progression toward androgen independence in human prostate cancer.

  2000cited by this paper
• AIB1 Is a Conduit for Kinase-Mediated Growth Factor Signaling to the Estrogen Receptor

  2000cited by this paper
• HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway.

  2000cited by this paper
• An androgen response element mediates LNCaP cell dependent androgen induction of the hK2 gene.

  2000cited by this paper
• A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase

  1999cited by this paper
• Phosphorylation of Human Estrogen Receptor α by Protein Kinase A Regulates Dimerization

  1999cited by this paper
• Phosphorylation of human estrogen receptor alpha by protein kinase A regulates dimerization.

  1999cited by this paper
• Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models.

  1999cited by this paper
• Sequence and structure-based prediction of eukaryotic protein phosphorylation sites.

  1999cited by this paper
• From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells.

  1999cited by this paper
• Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.

  1999cited by this paper
• Modulating nuclear receptor function: may the phos be with you.

  1999cited by this paper
• The Angelman Syndrome-Associated Protein, E6-AP, Is a Coactivator for the Nuclear Hormone Receptor Superfamily

  1999cited by this paper
• Proteasome-dependent degradation of the human estrogen receptor.

  1999cited by this paper
• Phosphorylation of Thyroid Hormone Receptors by Protein Kinase A Regulates DNA Recognition by Specific Inhibition of Receptor Monomer Binding*

  1998cited by this paper
• Lactacystin, Proteasome Function, and Cell Fate*

  1998cited by this paper
• An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter.

  1997cited by this paper
• Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice

  1997cited by this paper
• Two Androgen Response Regions Cooperate in Steroid Hormone Regulated Activity of the Prostate-specific Antigen Promoter (*)

  1996cited by this paper
• Androgen receptor phosphorylation.

  1996cited by this paper
• MAP kinase-dependent transcriptional coactivation by Elk-1 and its cofactor CBP.

  1996cited by this paper
• Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms.

  1995cited by this paper
• Heregulin Stimulates Mitogenesis and Phosphatidylinositol 3-Kinase in Mouse Fibroblasts Transfected with erbB2/neu and erbB3(*)

  1995cited by this paper
• Functional regulation of thyroid hormone receptor variant TR alpha 2 by phosphorylation

  1995cited by this paper
• Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase

  1995cited by this paper
• An antiestrogen: a phosphotyrosyl peptide that blocks dimerization of the human estrogen receptor.

  1995cited by this paper
• Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor.

  1995cited by this paper
• A specific inhibitor of the epidermal growth factor receptor tyrosine kinase.

  1994cited by this paper
• Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.

  1994cited by this paper
• Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.

  1994cited by this paper
• Phosphorylation selectively increases triiodothyronine receptor homodimer binding to DNA.

  1994cited by this paper
• Phosphorylation enhances the target gene sequence-dependent dimerization of thyroid hormone receptor with retinoid X receptor.

  1994cited by this paper
• The phosphorylation and DNA binding of the DNA-binding domain of the orphan nuclear receptor NGFI-B.

  1993cited by this paper
• Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.

  1992cited by this paper
• Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones.

  1992cited by this paper
• Modulation of glucocorticoid receptor function by protein kinase A.

  1992cited by this paper
• Hormone-dependent regulation of chicken progesterone receptor deoxyribonucleic acid binding and phosphorylation.

  1989cited by this paper
• Phosphorylation of serum response factor, a factor that binds to the serum response element of the c-FOS enhancer.

  1988cited by this paper
• Phosphorylation-induced binding and transcriptional efficacy of nuclear factor CREB

  1988cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei.

  1983cited by this paper
• Variants of 3T3 cells lacking mitogenic response to epidermal growth factor.

  1977cited by this paper
• Postnatal development of the testis, fighting behavior, and fertility in house mice.

  1973cited by this paper

• Phase II Randomized Study of MK-2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG-ACRIN E2809).

  2026cites this paper
• Historical Perspective of HER2 Testing and Treatment in Prostate Cancer.

  2026cites this paper
• HER2 as a molecular trojan horse in prostate cancer: mechanistic insights and therapeutic unlocks

  2025influential citation
• Looking beyond the ER, PR, and HER2: what’s new in the ARsenal for combating breast cancer?

  2025cites this paper
• SCAMP3 and EPS8 Cooperatively Regulate EGFR Signaling to Promote Enzalutamide Resistance and Metastatic Potential in Prostate Cancer

  2025cites this paper
• Localized high-risk prostate cancer harbors an androgen receptor activity–low subpopulation susceptible to HER2 inhibition

  2025cites this paper
• Single-cell and spatial RNA sequencing identify divergent microenvironments and progression signatures in early- versus late-onset prostate cancer

  2025cites this paper
• Localized high-risk prostate cancer harbors an androgen receptor low subpopulation susceptible to HER2 inhibition

  2024cites this paper
• The extent of androgen receptor and HER2 expression allows for targeted therapy in most cases of salivary duct carcinoma: analysis of clinical and histopathological data in a tertiary care center

  2024cites this paper
• ERBB3 Overexpression is Enriched in Diverse Patient Populations with Castration-sensitive Prostate Cancer and is Associated with a Unique AR Activity Signature

  2024cites this paper
• Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis in human and canine prostate cancer cells

  2024cites this paper
• Androgen drives melanoma invasiveness and metastatic spread by inducing tumorigenic fucosylation

  2024cites this paper
• Exploring the role of PI3K/AKT/mTOR inhibitors in hormone-related cancers: A focus on breast and prostate cancer.

  2023cites this paper
• Frequencies of an Immunogenic HER-2/neu Epitope of CD8+ T Lymphocytes Predict Favorable Clinical Outcomes in Prostate Cancer

  2023cites this paper
• Autocrine amphiregulin signaling sustains castration-resistant Ly6d+ prostate cancer cells.

  2023cites this paper
• Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis

  2022cites this paper
• The androgen receptor messenger RNA: what do we know?

  2022cites this paper
• Apocrine carcinoma of the breast: Review

  2022cites this paper
• The Extracellular Matrix Stiffening: A Trigger of Prostate Cancer Progression and Castration Resistance?

  2022cites this paper
• Phase II Study of Enzalutamide for Patients With Androgen Receptor–Positive Salivary Gland Cancers (Alliance A091404)

  2022cites this paper
• The testosterone paradox of advanced prostate cancer: mechanistic insights and clinical implications

  2022cites this paper
• Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer

  2021cites this paper
• MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT.

  2021cites this paper
• Transcriptional Inactivation of TP53 and the BMP Pathway Mediates Therapy-induced Dedifferentiation and Metastasis in Prostate Cancer

  2021cites this paper
• Biomarker Identification through Multiomics Data Analysis of Prostate Cancer Prognostication Using a Deep Learning Model and Similarity Network Fusion

  2021cites this paper
• Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer

  2021cites this paper
• Androgen Receptor Activation in Glioblastoma Can Be Achieved by Ligand-Independent Signaling through EGFR—A Potential Therapeutic Target

  2021cites this paper
• Metabolic Control of Sensory Neuron Survival by the p75 Neurotrophin Receptor in Schwann Cells

  2021cites this paper
• Androgen Receptor Pathway in Salivary Gland Cancer.

  2021cites this paper
• Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer

  2020influential citation
• GRB10 sustains AR activity by interacting with PP2A in prostate cancer cells

  2020cites this paper
• The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling

  2020cites this paper
• Natural Compounds in Prostate Cancer Prevention and Treatment: Mechanisms of Action and Molecular Targets

  2020cites this paper
• Microenvironment-Mediated Resistance to Anti-Androgen Therapy.

  2020cites this paper
• ACK1–AR and AR–HOXB13 signaling axes: epigenetic regulation of lethal prostate cancers

  2020cites this paper
• AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer

  2020cites this paper
• Cellular growth factors as prospective therapeutic targets for combination therapy in androgen independent prostate cancer (AIPC).

  2020cites this paper
• Data analysis algorithm for the development of extracellular miRNA-based diagnostic systems for prostate cancer

  2019cites this paper
• Maintenance Of Mammary Epithelial Phenotype By Transcription Factor Runx1 Through Mitotic Gene Bookmarking

  2019cites this paper
• ErbB-2 signaling in advanced prostate cancer progression and potential therapy

  2019cites this paper
• Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer

  2019cites this paper
• Analyse protéomique des réseaux de signalisation du récepteur aux androgènes modulés par l'Enzalutamide dans le cancer de la prostate résistant à la castration

  2019cites this paper
• Androgen receptor signaling regulates the transcriptome of prostate cancer cells by modulating global alternative splicing

  2019cites this paper
• Future Aspects of CDK5 in Prostate Cancer: From Pathogenesis to Therapeutic Implications

  2019cites this paper
• LRIG1 is a pleiotropic androgen receptor-regulated feedback tumor suppressor in prostate cancer

  2019cites this paper
• Current and potential targets for drug design in the androgen receptor pathway for prostate cancer

  2018cites this paper
• Discovery Of Piperlongumine Derivatives As Anti-Leukemic And Anti-Prostate Cancer Agents

  2018cites this paper
• HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumors

  2018cites this paper
• The Role of Androgen Receptor in Prostate Cancer

  2018cites this paper
• Over-Expression of Aryl Hydrocarbon Receptor (AhR) Enhances Src Kinase Activity to Functionally Induce AR Signaling and Promote Prostate Cancer Progression

  2018cites this paper
• Metastatic prostate cancer remains incurable, why?

  2018cites this paper
• The novel role of pyrvinium in cancer therapy

  2018cites this paper
• Breast Carcinoma: Updates in Molecular Profiling 2018.

  2018cites this paper
• Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer

  2018cites this paper
• New Insights in Prostate Cancer Development and Tumor Therapy: Modulation of Nuclear Receptors and the Specific Role of Liver X Receptors

  2018cites this paper
• Developing androgen receptor targeting for salivary gland cancers.

  2018cites this paper
• O‐Glycosylation‐mediated signaling circuit drives metastatic castration‐resistant prostate cancer

  2018cites this paper
• A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer

  2018cites this paper
• Prostate cancer health disparities: An immuno-biological perspective.

  2018cites this paper
• Importance de la co-dérégulation des voies RAS/MAPK et PI3K/AKT/mTOR dans la transformation épithéliale prostatique. Approche in vivo à l'aide d'un modèle dans les glandes accessoires de la Drosophile

  2018cites this paper
• Role of steroid receptor and coregulator mutations in hormone-dependent cancers

  2017cites this paper
• The oncolytic adenoviral AdΔΔ mutant sensitizesprostate cancercellsto mitoxantroneby promoting apoptosis and attenuating autophagy

  2017cites this paper
• AR Signaling in Breast Cancer

  2017cites this paper
• AR Signaling and the PI3K Pathway in Prostate Cancer

  2017cites this paper
• Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression.

  2017cites this paper
• Differential regulation of the androgen receptor by protein phosphatase regulatory subunits

  2017cites this paper
• A Standardized Wedelia chinensis Extract Overcomes the Feedback Activation of HER2/3 Signaling upon Androgen-Ablation in Prostate Cancer

  2017cites this paper
• Characterising novel phosphatase enzymes important in regulating androgen receptor function in the progression of castrate resistant prostate cancer

  2017cites this paper
• Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer.

  2017cites this paper
• Androgen Signaling in Prostate Cancer.

  2017cites this paper
• Stratifying Cancer Therapies by Molecular Interactions and Imaging

  2017cites this paper
• The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.

  2017cites this paper
• Antitumoral action of icaritin in LNCaP prostate cancer cells by regulating PEA3/HER2/AR signaling

  2016cites this paper
• Docetaxel Based Treatment for Metastatic Castration-Resistant Prostate Cancer-our Early Experience

  2016cites this paper
• Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide

  2016cites this paper
• Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer

  2016cites this paper
• ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer

  2016cites this paper
• The PI3K-mTOR Pathway in Prostate Cancer: Biological Significance and Therapeutic Opportunities

  2016cites this paper
• Resistance to PI3K Pathway Inhibition

  2016cites this paper
• The role of the epidermal growth factor receptor family in prostate cancer and their potential as therapeutic targets

  2016cites this paper
• Examination of Prostate Cancer Stem-like Cell Associated Factors for their Contribution Towards the Development of Castration Resistant Prostate Cancer

  2016cites this paper
• Plexin-B1 signalling promotes androgen receptor translocation to the nucleus

  2016cites this paper
• Anti-androgen therapy in triple-negative breast cancer

  2016cites this paper
• The Ron Receptor Tyrosine Kinase as a Mediator of Inflammation and Tumorigenesis

  2016cites this paper
• Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer

  2016cites this paper
• Internalization of secreted antigen–targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis

  2016cites this paper
• Integrated and Functional Genomics Analysis Validates the Relevance of the Nuclear Variant ErbB380kDa in Prostate Cancer Progression

  2016cites this paper
• Bioactive natural products for chemoprevention and treatment of castration-resistant prostate cancer.

  2016cites this paper
• Adenylyl cyclase activating polypeptide reduces phosphorylation and toxicity of the polyglutamine-expanded androgen receptor in spinobulbar muscular atrophy

  2016cites this paper
• Targeting the adaptive molecular landscape of castration-resistant prostate cancer

  2015cites this paper
• Expression of androgen receptor splice variants in clinical breast cancers

  2015cites this paper
• Combinatorial targeting of the androgen receptor for prostate cancer therapy

  2015cites this paper
• Androgen receptor (AR) inhibitor ErbB3-binding protein-1 (Ebp1) is not targeted by the newly identified AR controlling signaling axis heat-shock protein HSP27 and microRNA miR-1 in prostate cancer cells

  2015cites this paper
• ErbB-2 signaling plays a critical role in regulating androgen-sensitive and castration-resistant androgen receptor-positive prostate cancer cells.

  2015cites this paper
• Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target

  2015cites this paper
• Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.

  2015cites this paper
• Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism

  2015cites this paper
• Lemur Tyrosine Kinase 2, a novel target in prostate cancer therapy

  2015cites this paper
• Gene interference strategies as a new tool for the treatment of prostate cancer

  2015cites this paper
• Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer

  2015cites this paper